Total IQVIA prescriptions were 146,344 in the second quarter of 2023, an increase of 133% compared to the same period last year and 9% compared to the first quarter of 2023. Increase in ...

These milestones include (1) $1.00 per share payable if in any calendar year between closing and end of 2027, annual net sales of ZURZUVAE allocable to Supernus reach $250 million or more in the U ...

According to the deal, Supernus will pay up to $795m to acquire depression treatment specialist Sage. The contract value significantly eclipses the $469m offered by Biogen in January 2025, a ...

Supernus Pharmaceuticals, Inc. (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo ICR Healthcare (443) 213-0505 [email protected] This article contains syndicated content.

Supernus Pharmaceuticals (NASDAQ: SUPN), currently valued at $2.03 billion, has agreed to acquire Sage (LON: SGE) Therapeutics for $8.50 per share in cash, representing a total price of approximately ...

Supernus has offered $8.50 in cash for each share held and up to $3.50 per share in cash if certain milestones are achieved. Without the contingency offer, the deal is valued at about $561 million.

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.